CSPC Pharmaceutical Group Stock Forecast for 2023 - 2025 - 2030
Updated on 03/28/2024
CSPC Pharmaceutical Group Stock Forecast and Price Target
If the average 2024 price target of HK$9.27 recently set by six prominent experts for CSPC Pharmaceutical Group is met, there would be a potential upside of approximately 54.24% from the last closing price in March, 2024. The high estimate is HK$13.00, and the low is HK$5.90. If you want to invest in 1093 stock, you might also want to take a look at how its competitors are doing.
54.24% Upside
CSPC Pharmaceutical Group Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, CSPC Pharmaceutical Group has seen a decline in its Price, from HK$7.38 to HK$0.00 – a 100.00% decrease. For next year, analysts predict Fair Value of HK$8.66, which would mean an increase of 100.00%. Over the next seven years, experts predict that CSPC Pharmaceutical Group's Fair Value will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
600276 Stock Forecast | Jiangsu Hengrui Medicine | Buy |
15
|
¥43.60 | Buy/Sell | ¥56.49 | 23.85% |
BGNE Stock Forecast | BeiGene | Buy |
6
|
$164.53 | Buy/Sell | $285.19 | 67.14% |
1801 Stock Forecast | Innovent Biologics | Buy |
6
|
HK$40.00 | Buy/Sell | HK$50.60 | 27.20% |
600196 Stock Forecast | Shanghai Fosun Pharmaceutical ... | Outperform |
16
|
¥24.76 | Buy/Sell | ¥33.57 | 25.77% |
600062 Stock Forecast | China Resources Double-Crane P... | Buy |
16
|
¥21.19 | Buy/Sell | ¥26.00 | 8.54% |
CSPC Pharmaceutical Group Revenue Forecast for 2023 - 2025 - 2030
In the last two years, CSPC Pharmaceutical Group's Revenue has grown by 24.03%, rising from HK$24.94B to HK$30.94B. For next year, analysts predict Revenue of HK$38.15B, which would mean an increase of 23.32%. Over the next seven years, experts predict that CSPC Pharmaceutical Group's Revenue will grow at a rate of 29.47%.
CSPC Pharmaceutical Group Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, CSPC Pharmaceutical Group's Dividend per Share has grown by 72.73%, rising from HK$0.11 to HK$0.19. For next year, analysts predict Dividend per Share of HK$0.20, which would mean an increase of 5.26%. Over the next seven years, experts predict that CSPC Pharmaceutical Group's Dividend per Share will grow at a rate of 5.26%.
CSPC Pharmaceutical Group EBITDA Forecast for 2023 - 2025 - 2030
CSPC Pharmaceutical Group's EBITDA has grown In the last two years, rising from HK$6.10B to HK$7.61B – a growth of 24.80%. In the next year, analysts believe that EBITDA will reach HK$10.11B – an increase of 32.88%. For the next seven years, experts predict that CSPC Pharmaceutical Group's EBITDA will grow at a rate of 44.33%.
CSPC Pharmaceutical Group EBIT Forecast for 2023 - 2025 - 2030
CSPC Pharmaceutical Group's EBIT has seen impressive growth In the last two years, rising from HK$5.42B to HK$6.76B – a growth of 24.83%. In the next year, analysts believe that EBIT will reach HK$8.81B – an increase of 30.40%. For the next seven years, the forecast is for EBIT to grow by 30.80%.
CSPC Pharmaceutical Group EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, CSPC Pharmaceutical Group has seen a decline in its EPS, from HK$0.52 to HK$0.00 – a 100.00% decrease. For next year, analysts predict EPS of HK$0.61, which would mean an increase of 100.00%. Over the next seven years, experts predict that CSPC Pharmaceutical Group's EPS will grow at a rate of 100.00%.